<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606018</url>
  </required_header>
  <id_info>
    <org_study_id>LISPRO-25-CL</org_study_id>
    <nct_id>NCT03606018</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects</brief_title>
  <official_title>A Randomized Duble Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Lispro Mix 25 (LLC &quot;GEROPHARM&quot;, Russia) Versus Humalog® Mix 25 (Eli Lilly) in Healthy Subjects Using the Euglycemic Clamp Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and pharmacodynamics study Study of 2 formulation of insulin lispro mix 25
      (Insulin Lispro Mix 25 GEROPHARM vers. Humalog® Mix 25 Eli Lilly)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized duble blinded two-way crossover single-dose pharmacokinetics and
      pharmacodynamics study of Insulin Lispro Mix 25 (LLC &quot;GEROPHARM&quot;, Russia) versus Humalog® Mix
      25 (Eli Lilly) in normal healthy subjects using the euglycemic clamp technique
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2017</start_date>
  <completion_date type="Actual">July 13, 2017</completion_date>
  <primary_completion_date type="Actual">July 13, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This study was blinded for Sponsor, investigators and analytical laboratory</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-0.5, 0 hour (pre-dose) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14 hour post-dose</time_frame>
    <description>Pharmacokinetics of insulin lispro by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>-0.5, 0 hour (pre-dose) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14 hour post-dose</time_frame>
    <description>Pharmacokinetics of insulin Lispro by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Clamp Study</condition>
  <arm_group>
    <arm_group_label>Insulin Lispro Mix 25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® Mix 25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro Mix 25</intervention_name>
    <description>insulin lispro biphasic in doses 0.4 ME/kg</description>
    <arm_group_label>Insulin Lispro Mix 25</arm_group_label>
    <other_name>insulin lispro biphasic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog® Mix 25</intervention_name>
    <description>insulin lispro biphasic in doses 0.4 ME/kg</description>
    <arm_group_label>Humalog® Mix 25</arm_group_label>
    <other_name>insulin lispro biphasic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent.

          2. Caucasian males having a confirmed healthy diagnosis as per data of standard clinical,
             laboratory, and instrumental examination methods.

          3. Age of 18-50 (both incl.).

          4. Body mass index equal to 18.5-27.0 kg/m2.

          5. Volunteers' consent to all restrictions imposed during the study, including adequate
             methods of contraception.

        Exclusion Criteria:

          1. Acute inflammatory diseases within 3 weeks before the screening period

          2. Episodes of hypoglycemia in the anamnesis, or the presence in the family history of
             cases of a verified diagnosis of diabetes mellitus in the immediate family

          3. Fasting plasma glucose&gt; 6.1 mmol / L

          4. HbA1C&gt; 6%

          5. Oral glucose tolerance test - blood glucose level ≥ 7.8 mmol / l (2 hours after
             loading with glucose)

          6. Deep vein thrombosis of lower extremities in a history of life or in a family history.

          7. Nicotine dependence (use of tobacco less than 6 months before the start of screening)

          8. Taking medications, phytopreparations, biologically active supplements less than 14
             days before screening

          9. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5
             liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information
             about alcoholism.

         10. Donor blood donation in excess of 450 ml, less than 2 months before the study.

         11. Participation in a clinical trial of any medications less than 3 months before the
             start of screening

         12. Positive test results for hepatitis C or hepatitis B, HIV, syphilis.

         13. Anamnesis information about drug and / or drug dependence and / or substance abuse.

         14. Positive test for alcohol content in the exhaled air.

         15. A positive test for the content of drugs in the urine.

         16. Presence of suspicions of an inflammatory disease of the urinary system as a result of
             urinalysis.

         17. Presence of mental illnesses in the anamnesis.

         18. Mental, physical and other reasons that do not allow to adequately assess their
             behavior and properly fulfill the conditions of the research protocol.

         19. Any other conditions that make it difficult, according to the informed opinion of the
             investigating physician, that volunteer participation in studies

         20. Increased sensitivity in the history of heparin, insulin or any of the excipients of
             the study drugs

         21. Weighed allergic anamnesis

         22. Abnormalities of the ECG and laboratory parameters from the norms

         23. Deviations in basic vital signs: systolic blood pressure is below 100 mm Hg. or above
             130 mm Hg, the diastolic blood pressure is below 70 mm Hg. or above 90 mm Hg; heart
             rate less than 60 or greater than 80

         24. Deviations in basic vital signs: systolic blood pressure &lt;100 mmHg. or&gt; 130 mm Hg,
             diastolic blood pressure &lt;70 mm Hg. Art. or&gt; 90 mm Hg. Art. heart rate &lt;60 or&gt; 80 per
             minute.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>In women of childbearing age, the cyclicity of the hormonal status may affect insulin sensitivity at different stages of the study. Therefore, to exclude the influence of the cyclicity factor of the menstrual period on insulin sensitivity in women, only males have been included in the this study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FSBI&quot;ENDOCRINOLOGY NMRC&quot; Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLL &quot;BioEq&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Insulin Lispro</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

